For resectable early-stage NSCLC, improved event-free survival seen with pembrolizumab, regardless of N status, clinical stage, type of surgery
Survival similar among racial and ethnic groups; ECOG performance status linked to survival
First-line atezolizumab monotherapy is associated with improved overall survival compared with single-agent chemotherapy
Lack of significant overall survival advantage seen for indefinite-duration versus fixed-duration immunotherapy
Improvement seen compared with chemotherapy alone for first-line treatment of advanced non-small cell lung cancer
Integration of definitive local therapy relevant if technically feasible and clinically safe to all disease sites
Benefits seen in terms of pathologic complete response and event-free survival for resectable non-small cell lung cancer
Mutation frequencies of <em>EGFR</em> and <em>KRAS</em> were 30 and 10 percent, respectively, and 23 and 13 percent, respectively, for Mexican and Colombian patients